Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies

Neurology. 2007 May 15;68(20):1726-9. doi: 10.1212/01.wnl.0000261920.03297.64.

Abstract

Cholinesterase inhibitors (ChEIs) are effective symptomatic treatments in dementia with Lewy bodies (DLB), although effects on pathologic mechanisms are unknown. In the first human autopsy study examining the impact of ChEI treatment on brain pathology, we compared treated patients with DLB with matched untreated patients for cortical beta-amyloid (Abeta) and tau pathologies. Treated patients with DLB had significantly less parenchymal Abeta deposition, which is relevant to disease management and treatment of dementia patients using ChEI.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Amyloid beta-Peptides / analysis*
  • Autopsy
  • Cerebral Cortex / chemistry*
  • Cerebral Cortex / pathology
  • Cholinesterase Inhibitors / pharmacology*
  • Cholinesterase Inhibitors / therapeutic use
  • Clinical Trials as Topic
  • Cohort Studies
  • Donepezil
  • Drug Evaluation
  • Female
  • Galantamine / therapeutic use
  • Humans
  • Indans / therapeutic use
  • Lewy Body Disease / drug therapy*
  • Lewy Body Disease / metabolism
  • Lewy Body Disease / pathology
  • Male
  • Middle Aged
  • Neuroprotective Agents / pharmacology*
  • Neuroprotective Agents / therapeutic use
  • Phenylcarbamates / therapeutic use
  • Piperidines / therapeutic use
  • Prospective Studies
  • Rivastigmine
  • Tacrine / therapeutic use
  • Tauopathies / drug therapy*
  • Tauopathies / metabolism
  • Tauopathies / pathology
  • tau Proteins / analysis

Substances

  • Amyloid beta-Peptides
  • Cholinesterase Inhibitors
  • Indans
  • MAPT protein, human
  • Neuroprotective Agents
  • Phenylcarbamates
  • Piperidines
  • tau Proteins
  • Galantamine
  • Tacrine
  • Donepezil
  • Rivastigmine